Diabetes

A new therapy for treating Type 1 diabetes

October 20, 2021

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes

HSCI co-director leads multi-institutional center to advance type 1 diabetes research

February 23, 2021

The JDRF Center of Excellence in New England will accelerate beta cell replacement therapy

Harvard Stem Cell Institute (HSCI) co-director Douglas Melton, Ph.D., will lead a new multi-institutional center funded by JDRF to advance type 1 diabetes research. The JDRF Center of Excellence in New England will focus on the transplantation of beta cells, the insulin-producing cells of the pancreas that are attacked by the immune system during type 1 diabetes.

The center is also led by JDRF scientific staff leader Esther Latres, Ph.D. Other collaborators include...

Read more about HSCI co-director leads multi-institutional center to advance type 1 diabetes research

Cell therapy for all

November 1, 2018

Chad Cowan is on a quest for the universal donor, which would make cell therapy available to populations – not just individuals.

  • Harvard scientist Chad Cowan aims to make off-the-shelf cellular products, and democratize access to new medicines.
  • His lab is working to make cellular therapies that can work for anyone, not just a single patient. 
  • Their ambitious goal is to modify therapeutic cells that can be transplanted into many people, without being rejected.

...

Read more about Cell therapy for all